Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Cowen

Share on StockTwits

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reiterated by research analysts at Cowen in a report issued on Tuesday, AnalystRatings.com reports. They currently have a $213.00 price target on the biotechnology company’s stock. Cowen’s target price would indicate a potential upside of 62.86% from the stock’s current price.

Several other equities analysts have also commented on SRPT. Leerink Swann reissued an “outperform” rating and set a $216.00 price target (up from $186.00) on shares of Sarepta Therapeutics in a research report on Friday, December 13th. Janney Montgomery Scott boosted their price target on Sarepta Therapeutics from $160.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. HC Wainwright boosted their price target on Sarepta Therapeutics from $160.00 to $260.00 in a research report on Friday, December 13th. Nomura reissued a “buy” rating and set a $230.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, December 25th. Finally, Guggenheim initiated coverage on Sarepta Therapeutics in a research report on Friday, November 1st. They set a “buy” rating and a $183.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company. Sarepta Therapeutics has an average rating of “Buy” and an average price target of $197.81.

Shares of NASDAQ SRPT traded up $0.55 during midday trading on Tuesday, hitting $130.79. The stock had a trading volume of 286,747 shares, compared to its average volume of 1,026,953. The company has a market capitalization of $9.54 billion, a price-to-earnings ratio of -23.95 and a beta of 2.27. Sarepta Therapeutics has a 1-year low of $72.05 and a 1-year high of $158.80. The company has a quick ratio of 5.54, a current ratio of 6.31 and a debt-to-equity ratio of 0.49. The company has a fifty day moving average price of $123.27 and a 200 day moving average price of $112.15.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.35). The company had revenue of $99.04 million for the quarter, compared to analyst estimates of $98.49 million. Sarepta Therapeutics had a negative return on equity of 55.44% and a negative net margin of 169.87%. The business’s revenue was up 26.2% on a year-over-year basis. During the same period last year, the firm posted ($1.15) earnings per share. On average, research analysts forecast that Sarepta Therapeutics will post -6.34 EPS for the current year.

In other news, EVP Alexander Cumbo sold 42,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $125.50, for a total transaction of $5,271,000.00. Following the completion of the sale, the executive vice president now directly owns 13,888 shares of the company’s stock, valued at $1,742,944. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP David T. Howton sold 25,000 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $105.00, for a total value of $2,625,000.00. Following the sale, the executive vice president now directly owns 24,388 shares of the company’s stock, valued at $2,560,740. The disclosure for this sale can be found here. In the last 90 days, insiders sold 192,000 shares of company stock valued at $23,583,500. Insiders own 6.60% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in SRPT. UBS Asset Management Americas Inc. raised its position in Sarepta Therapeutics by 16.6% during the second quarter. UBS Asset Management Americas Inc. now owns 296,565 shares of the biotechnology company’s stock valued at $45,063,000 after buying an additional 42,263 shares during the period. Pictet Asset Management Ltd. raised its position in Sarepta Therapeutics by 70.6% during the second quarter. Pictet Asset Management Ltd. now owns 458,183 shares of the biotechnology company’s stock valued at $69,621,000 after buying an additional 189,628 shares during the period. Envestnet Asset Management Inc. increased its position in Sarepta Therapeutics by 34.6% in the 3rd quarter. Envestnet Asset Management Inc. now owns 4,024 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 1,034 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Sarepta Therapeutics in the 2nd quarter worth about $14,113,000. Finally, United Capital Financial Advisers LLC increased its position in Sarepta Therapeutics by 4.3% in the 2nd quarter. United Capital Financial Advisers LLC now owns 15,623 shares of the biotechnology company’s stock worth $2,374,000 after purchasing an additional 643 shares during the last quarter. 97.65% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Recommended Story: Rule of 72

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.